First Patient Receives Keytruda Combination in Ovarian Cancer Trial

Investigators have administered Keytruda and ONC-392 the first patients with platinum resistant ovarian cancer.

The first patient has received their dose of the combination ONC-392 and Keytruda (pembrolizumab) in a phase 2 study, according to a press release.

The study, PRESERVE-004, is evaluating the combination in adults with platinum-resistant ovarian cancer that has progressed on a prior therapy containing Avastin (bevacizumab). The researchers plan on enrolling approximately 58 patients across 20 cancer centers across the United States.

The main goal of the trial is objective response rate (the rate of a measurable response to the treatment) as well as treatment- and immune-related side effects.

Patients participating in the study will receive the combination once every three weeks for 24 months.

“ … We are thrilled to dose the first patient at our institution with this innovative immunotherapy combination, which hopes to address the unmet need in platinum-resistant ovarian cancer,” said Dr. Joyce Barlin, lead author on the study, in the release.

ON-392 is a target preserving anti-CTLA-4 antibody as has previously received fast-track designation from the Food and Drug Administrations as monotherapy for patients with non-small cell lung cancer whose disease is immunotherapy-resistant. Additionally, the therapy may not only reduce toxicity but also increase therapeutic efficacy, according to the release.

The estimated study completion date is June 30, 2026.


For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.